Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

antibiotic-resistance-pill-running-from-bacteria-1500

The global rise in antibiotic resistance threatens infection prevention and cure

May 20, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance, antimicrobial resistance, feature, pharma

Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic …
Feature
abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019 Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
News
boehringer_biberach_germany_copy

Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke

May 20, 2019 Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure

Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019 Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
News
roche__tree

Phase 1/2 data show Roche’s entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents

May 17, 2019 Medical Communications, Research and Development Cancer, Roche, entrectinib, pharma

Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 17, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
News
lance2

A day in the life: Lance Hill, CEO at Within3

May 17, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing A day in the life, Interview, Within3, feature

Could you give a short history of how you came to be in your current role? I’ve spent my entire …
Feature

Insider Interview: Paving paths in prostate cancer

May 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …
Feature

Pfizer’s abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis

May 16, 2019 Research and Development Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that …
News
5204602349_c87b204860_z

ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial

May 16, 2019 Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks

Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …
News

EUSA Pharma bolsters senior leadership team with two appointments

May 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eusa Pharma, appointment

Rare disease and oncology biopharma firm EUSA Pharma has revealed two new additions to its senior leadership team in two …
Appointment
123_dott_paolo_chiesi_550

Paola Chiesi awarded honorary doctorate by Karolinska Institutet

May 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Paolo Chiesi, Vice President of the Chiesi Group, has been made an Honorary Doctor at the Karolinska Institutet – a …
Appointment
index_ph001

Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel

May 15, 2019 Research and Development, Sales and Marketing Daiichi Sankyo, FDA, pexidartinib, pharma, quizartinib

Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for …
News

Pfizer & Merck’s Inlyta combo becomes first FDA-approved anti-PD-L1 therapy for kidney cancer

May 15, 2019 Research and Development, Sales and Marketing FDA, Merck KGaA, Pfizer, inylta, pharma, renal cell carcinoma

The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). …
News

NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza

May 15, 2019 Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy

NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026